ABOUT WEX PHARMA
TTX for Chemotherapy-Induced Neuropathic Pain
TTX for Cancer-Related Pain
TTX Clinical Experience
Chemotherapy-Induced Neuropathic Pain
The Drug Development Process
Posters and Presentations
Publications, Posters and Presentations
May 17, 2015
WEX Pharmaceuticals Inc. announces presentation of preclinical data on chemotherapy-induced peripheral neuropathy and burn injury pain at the 2015 American pain society conference on its lead compound, HALNEURON™ (TTX)
WEX Pharmaceuticals Inc.
Dedicated to the Discovery, Development, Manufacture, and Commercialization of innovative drug products to treat local and systemic pain.
TEC-006 - A clinical trial for the treatment of moderate to severe inadequately controlled cancer-related pain.
TTX-CINP-201 - A clinical trial for the treatment of moderate to severe neuropathic pain caused by chemotherapy in patients with cancer.
TTX-CINP-201 trial featured on NBC-2 news in Port Charlotte Florida.
CK Life Sciences Int'l.,(Holdings) Inc. (0775.HK) is engaged in research, development and commercialisation of innovative biotechnology products applicable to human health and environmental sustainability.
Copyright WEX Phamaceuticals Inc. All Rights Reserved.